SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback